In the Claims

1(Currently Amended). A compound of the structural formula I:



where

Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof: wherein,

R represents hydrogen, or C_{1-6} alkyl;

X represents $-(CHR_7)_p-$, or $-(CHR_7)_pCO-$;

Y represents $-CO(CH_2)_n-$, $(CH_2)_n$, -CH(OR)-, OR_6, or SR_6;

Z=O or S;

M1, M2, and M3 are independently CH or N;

Q represents ~~CR_Y~~, N, ~~or O, wherein R_2 is absent when Q is O~~;

R_Y represents H, C_{1-6} alkyl, $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_nC_{3-10}$ heterocyclyl, $-(CH_2)_nC_{5-10}$ heteroaryl, or $-(CH_2)_nC_{6-10}$ aryl;

R_w represents H, C_{1-6} alkyl, $-C(O)C_{1-6}$ alkyl, $-C(O)OC_{1-6}$ alkyl, $-SO_2N(R)_2$, $-SO_2C_{1-6}$ alkyl, $-SO_2C_{6-10}$ aryl, NO_2, CN or $-C(O)N(R)_2$;

R_2 represents hydrogen, C_{1-10} alkyl, OH, C_{2-6} alkenyl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_n(CHR_7)_q(CH_2)_mC_{1-6}$ alkoxy, -

~~$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-8}$ cycloalkyl,~~ $(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-8}$cycloalkenyl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-10}$ heterocyclyl, -$N(R)_2$, -COOR, or -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{6-10}$ aryl, said alkyl, cycloalkyl, heterocyclyl, or aryl optionally substituted with 1-5 groups selected from R^a;

R_3 represents hydrogen, C_{1-10} alkyl, C_{2-6} alkenyl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-8}$ cycloalkyl, -$(CH_2)_n(CHR_7)_q(CH_2)_m$cycloalkenyl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-10}$ heterocyclyl, -$(CH_2)_n(CHR_7)_q(CH_2)_m$COOR, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{6-10}$ aryl, -$(CH_2)_n(CHR_7)_q(CH_2)_m$$NHR_8$, -$(CH_2)_n(CHR_7)_q(CH_2)_mN(R)_2$, -$(CH_2)_n(CHR_7)_q(CH_2)_mN(R)_3$, -$(CH_2)_n(CHR_7)_q(CH_2)_mN(R_8)_2$, -$(CH_2)_n(CHR_7)_q(CH_2)_m$NHCOOR, -$(CH_2)_n(CHR_7)_q(CH_2)_mN(R_8)CO_2R$, -$(CH_2)_n(CHR_7)_q(CH_2)_mN(R_8)$COR, -$(CH_2)_n(CHR_7)_q(CH_2)_m$NHCOR, -$(CH_2)_n(CHR_7)_q(CH_2)_m$CONH($R_8$), aryl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{1-6}$ alkoxy, CF_3, -$(CH_2)_n(CHR_7)_q(CH_2)_mSO_2R$, -$(CH_2)_n(CHR_7)_q(CH_2)_mSO_2N(R)_2$, -$(CH_2)_n(CHR_7)_q(CH_2)_mCON(R)_2$, -$(CH_2)_n(CHR_7)_q(CH_2)_m$CONHC$(R)_3$, -$(CH_2)_n(CHR_7)_q(CH_2)_m$CONHC$(R)_2CO_2R$, -$(CH_2)_n(CHR_7)_q(CH_2)_mCOR_8$, nitro, cyano or halogen, said alkyl, cycloalkyl, alkoxy, heterocyclyl, or aryl optionally substituted with 1-5 groups of R^a;

~~or, when Q equals CR_Y or N, R_2 and R_3 taken together with the intervening CR_Y or N form a 3-10 membered carbocyclic or heterocyclic ring or fused ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from R^a;~~

R_4 and R_5 independently represent hydrogen, C_{1-6} alkoxy, OH, C_{1-6} alkyl, C_{1-6} alkyl-S, C_{1-6} alkyl-CO-, C_{1-6} alkenyl, C_{3-8} cycloalkoxy, C_{3-8} cycloalkyl, C_{3-8} cycloalkyl-S, C_{3-8} cycloalkyl-CO-, COOR, SO_3H, -$O(CH_2)_nN(R)_2$, -$O(CH_2)_nCO_2R$, -$OPO(OH)_2$, CF_3, -$N(R)_2$, nitro, cyano, C_{1-6} alkylamino, or halogen;

R_6 represents hydrogen, C_{1-10} alkyl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{6-10}$ aryl, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{5-10}$ heteroaryl, NR_cR_d, -NR-$(CH_2)_n(CHR_7)_q(CH_2)_mC_{6-10}$ aryl,
-N-$((CH_2)_n(CHR_7)_q(CH_2)_mC_{6-10}$ aryl$)_2$, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-10}$ heterocyclyl, -NR-$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-10}$ heterocyclyl, -N-$((CH_2)_n(CHR_7)_q(CH_2)_mC_{3-10}$ heterocyclyl$)_2$ (C_{6-10} aryl)O-, -$(CH_2)_n(CHR_7)_q(CH_2)_mC_{3-8}$ cycloalkyl, -COOR, -

$C(O)CO_2R$, said aryl, cycloalkyl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from R^a;

R_c and R_d independently represent H, C1-6 alkyl, C_{2-6} alkenyl, $-(CH_2)_nC_{6-10}$ aryl, $-(CH_2)_nC_{5-10}$ heteroaryl, C_{1-6} alkylSR, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, or $-(CH_2)_nC_{3-8}$ cycloalkyl;

or R_c and R_d taken together with the intervening N atom form a 4-10 membered heterocyclic carbon ring optionally interrupted by 1-2 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from R^a;

R_7 represents hydrogen, C_{1-6} alkyl, $-(CH_2)_nCOOR$ or $-(CH_2)_nN(R)_2$,

R_8 represents $-(CH_2)_nC_{3-8}$ cycloalkyl, $-(CH_2)_n$ 3-10 heterocyclyl, C_{1-6} alkoxy or $-(CH_2)_nC_{5-10}$ heteroaryl, $-(CH_2)_nC_{6-10}$ aryl said cycloalkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from R^a;

R^a represents F, Cl, Br, I, CF_3, $N(R)_2$, NO_2, CN, $-COR_8$, $-CONHR_8$, $-CON(R_8)_2$, $-O(CH_2)_nCOOR$, $-NH(CH_2)_nOR$, -COOR, $-OCF_3$, -NHCOR, $-SO_2R$, $-SO_2NR_2$, -SR, (C_1-C_6 alkyl)O-, $-(CH_2)_nO(CH_2)_mOR$, $-(CH_2)_nC_{1-6}$ alkoxy, (aryl)O-, -OH, (C_1-C_6 alkyl)$S(O)_m$-, H_2N-C(NH)-, (C_1-C_6 alkyl)C(O)-, (C_1-C_6 alkyl)OC(O)NH-, -(C_1-C_6 alkyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_1-C_6 alkyl)-C_{3-10} heterocyclyl-R_w, $-(CH_2)_n$-Z^1-C(=Z^2)$N(R)_2$, -(C_{2-6} alkenyl)$NR_w(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$O(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)$S(CH_2)_nC_{3-10}$ heterocyclyl-R_w, -(C_{2-6} alkenyl)-C_{3-10} heterocyclyl-R_w, -(C_{2-6} alkenyl)-Z^1-C(=Z^2)$N(R)_2$, $-(CH_2)_nSO_2R$, $-(CH_2)_nSO_3H$, $-(CH_2)_nPO(OR)_2$, $-(CH_2)_nOH$, $-(CH_2)_n(CHR_7)_q(CH_2)_mOPO(OR)_2$, C_{3-10}cycloalkyl, C_{6-10} aryl, C_{3-10} heterocyclyl, C_{2-6} alkenyl, and C_1-C_{10} alkyl, said alkyl, alkenyl, alkoxy, heterocyclyl and aryl optionally substituted with 1-3 groups selected from C_1-C_6 alkyl, CN, NO_2, $-(CH_2)_nOH$, $-(CH_2)_nOPO(OR)_2$, $CON(R)_2$ and COOR;

Z^1 and Z^2 independently represents NR_w, O, CH_2, or S;

m is 0-3;
n is 0-3;
p is 0-3 and
q is 0-1.

2(Original). A compound according to claim 1 wherein Q is –N- and Y is $-CO(CH_2)_n$.

3(Original). A compound according to claim 2 wherein n=0, Z is S, and R_6 is C_{1-6} alkyl, $(CH_2)_nC_{6-10}$ aryl, $(CH_2)_nC_{5-10}$ heteroaryl, $(CH_2)_nC_{3-10}$ heterocyclyl, NR_cR_d or $(CH_2)_nC_{3-8}$ cycloalkyl, said alkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

4(Original). A compound according to claim 3 wherein M1, M2 and M3 are CH, X is $-(CHR_7)_pCO-$, p is 1-3 , R_2 is C_{1-10} alkyl or C_{1-6} alkylOH and R_3 is $(CH_2)_nC_{3-10}$ heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

5. Cancel.

6(Original). A compound according to claim 2 wherein n=0, Z is O, and R_6 is C_{1-6} alkyl, $(CH_2)_nC_{6-10}$ aryl, $(CH_2)_nC_{5-10}$ heteroaryl, $(CH_2)_nC_{3-10}$ heterocyclyl, NR_cR_d or $(CH_2)_nC_{3-8}$ cycloalkyl, said alkyl, aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

7(Original). A compound according to claim 6 wherein M1, M2 and M3 are CH, X is $-(CHR_7)_pCO-$, p is 1-3 , R_2 is C_{1-10} alkyl or C_{1-6} alkylOH and R_3 is $(CH_2)_nC_{3-10}$ heterocyclyl, said heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

8. Cancel.

9. Cancel.

10(Original). A compound according to claim 1 where a free hydroxyl group is present, said hydroxyl group optionally derivatized to give a phosphate group represented as $-OPO(OH)_2$.

11(Currently Amended). A compound which is:

N,*N*-Bibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]acetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*,*N*-diisobutylacetamide ,

~~*N*-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-propylacetamide,~~

~~*N*-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-ethylacetamide,~~

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*,*N*-dipropylacetamide,

N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-ethylacetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*,*N*-bis(3-methylbutyl)acetamide,

2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,

N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-propylacetamide,

~~1-{5-Methoxy-3-[2-(trans-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzofuran-2-yl}-2,2-dimethylpropan-1-one,~~

~~1-{5-Methoxy-3-[2-(cis-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzofuran-2-yl}-2,2-dimethylpropan-1-one,~~

~~1-(3-{2-[Trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-methoxy-1-benzofuran-2-yl)-2,2-dimethylpropan-1-one,~~

~~1-(3-{2-[Cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-methoxy-1-benzofuran-2-yl)-2,2-dimethylpropan-1-one,~~

N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]acetamide,

N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-ethylacetamide,

~~1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-3,3-dimethylbutan-2-one,~~

2-(2-Benzoyl-5-methoxy-1-benzofuran-3-yl)-*N*,*N*-dibutylacetamide,

~~1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-3,3-dimethylpentan-2-one~~

2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*,*N*-di-n-butylacetamide;

2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*,*N*-diisobutylacetamide;

~~*N*-(cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-propylacetamide;~~

~~*N*-cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-ethylacetamide;~~

2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*,*N*-dipropylacetamide;

N-butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-ethylacetamide;
2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide;
N-butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-propylacetamide;
2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*,*N*-bis(3-methylbutyl)acetamide;
~~1-{5-methoxy-3-[2-(trans-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-{5-methoxy-3-[2-(cis-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-methoxy-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-methoxy-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-*N*-ethylacetamide;
~~1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzothien-3-yl]-3,3-dimethylbutan-2-one;~~
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-methylacetamide;
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1-benzofuran-3-yl]-*N*-methyl-*N*-(3-methylbutyl)acetamide;
2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*,*N*-di-n-butylacetamide;
2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*,*N*-diisobutylacetamide;
~~*N*-(cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-propylacetamide;~~
~~*N*-cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-ethylacetamide;~~
2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*,*N*-dipropylacetamide;
N-butyl-2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-ethylacetamide;
2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide;
N-butyl-2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-propylacetamide;
2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*,*N*-bis(3-methylbutyl)acetamide;
~~1-{5-fluoro-3-[2-(trans-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-{5-fluoro-3-[2-(cis-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-fluoro-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-5-fluoro-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-5-fluoro-1-benzothien-3-yl]-*N*-ethylacetamide;
2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*,*N*-di-n-butylacetamide;
2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*,*N*-diisobutylacetamide;

~~*N*-(cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-propylacetamide;~~
~~*N*-cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-ethylacetamide;~~
2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*,*N*-dipropylacetamide;
N-butyl-2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-ethylacetamide;
2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide;
N-butyl-2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-propylacetamide;
2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*,*N*-bis(3-methylbutyl)acetamide;
~~1-{3-[2-(trans-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-{3-[2-(cis-octahydroisoquinolin-2(1*H*)-yl)-2-oxoethyl]-1-benzothien-2-yl}-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
~~1-(3-{2-[(cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-1-benzothien-2-yl)-2,2-dimethylpropan-1-one;~~
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-1-benzothien-3-yl]-*N*-ethylacetamide;
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

12(Currently Amended). A method for the treatment ~~Use of a compound of formula I in claim 1 for the manufacture of a medicament for the treatment of~~ ocular hypertension or glaucoma comprising administering to a patient in need thereof a therapeutically effective amount of a compound of structural formula I.

13(Original). Use of a compound of formula I in claim 1 for the manufacture of a medicament for the treatment of macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a neuroprotective effect.

14. Cancel.

15. Cancel.

16(Original). A composition comprising a compound of formula I of claim 1 and a pharmaceutically acceptable carrier.

17(Original). The composition according to Claim 16 wherein the compound of formula I is applied as a topical formulation, said topical formulation

administered as a solution or suspension and optionally contains xanthan gum or gellan gum.

18(Original). A composition according to claim 17 wherein one or more of an active ingredient belonging to the group consisting of: β-adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

19(Original). A composition according to claim 18 wherein the β-adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imdazol-6-ol fumarate or 2-(3-chloro-6-methoxy-indazol-1-yl)-1-methyl-ethylamine.